Ameluz aminolevulinic acid: Phase III started

Biofrontera began an observer-blind, European Phase III trial to compare topical Ameluz plus daylight PDT vs. topical Metvix methyl aminolevulinate plus daylight PDT in about 50 patients. Patients will receive each treatment to separate areas of the face or scalp containing 3-9 mild to moderate actinic keratosis lesions. ...